Literature DB >> 3717932

Pharmacokinetics and dose proportionality of cefpimizole in normal humans after intramuscular administration.

D B Lakings, E Novak, J M Friis, C M Lunan, L M Paxton.   

Abstract

The pharmacokinetics of cefpimizole (free acid equivalents of cefpimizole sodium), a broad-spectrum cephalosporin antibiotic, were evaluated after intramuscular administration of single doses (dose range, 100 to 1,000 mg) and multiple doses (dose range, 500 to 2,000 mg) given b.i.d. for 6 or 11 days. The kinetics after intramuscular administration correspond to a one-compartment model with first-order input. The apparent volume of distribution of the absorbed dose averaged 18.6 +/- 3.4 (standard deviation) liters for 58 individuals; the absorption-phase and elimination-phase rate constants averaged 2.53 +/- 1.16 h-1 (half-life, 0.27 h) and 0.338 +/- 0.041 h-1 (half-life, 2.05 h), respectively; and the mean residence time was 3.43 +/- 0.43 h. The total body clearance of the absorbed dose after single-dose intramuscular administration was 102 +/- 13 ml/min. The primary route of elimination was renal with 73 to 83% of the administered dose excreted in the urine as unchanged drug. Renal clearance averaged 81 +/- 13 ml/min. Dose proportionality was obtained from area under the plasma curve, concentration maximum in plasma, and cumulative urinary excretion levels. Multiple-dose evaluation of intramuscular administration of cefpimizole indicated no apparent change in the absorption or elimination phases after b.i.d. dosing for 6 or 11 days. The kinetic parameters determined from multiple-dose plasma and urine levels were in close agreement with the same parameters calculated from single-dose results. No apparent accumulation of cefpimizole occurred, and nondetectable levels of drug were observed in the 24-h plasma and 24- to 48-h urine specimen after administration of the last dose. The kinetics of cefpimizole after intramuscular administration were similar to the kinetics obtained after intravenous infusion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3717932      PMCID: PMC176389          DOI: 10.1128/AAC.29.2.271

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Comparative pharmacokinetics of cefoperazone and cefamandole.

Authors:  S Srinivasan; E L Francke; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

2.  Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.

Authors:  K S Israel; H R Black; G L Brier; J D Wolny; K A DeSante
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

3.  Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers.

Authors:  S Srinivasan; K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

4.  Synthesis and antibacterial activity of 6- and 7-[2-(5-carboxyimidazole-4-carboxamido)phenylacetamido]-penicillins and cephalosporins.

Authors:  N Yasuda; H Iwagami; E Nakanishi; T Nakamiya; Y Sasaki; T Murata
Journal:  J Antibiot (Tokyo)       Date:  1983-03       Impact factor: 2.649

5.  Pharmacology of ceftizoxime compared with that of cefamandole.

Authors:  H C Neu; S Srinivasan
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

6.  [Kinetics of cefotaxime in healthy subjects (author's transl)].

Authors:  J F Acar; J Guibert; M D Kitzis
Journal:  Nouv Presse Med       Date:  1981-02-26

7.  In vitro activity and beta-lactamase stability of U-63196E, a novel cephalosporin.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

8.  The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function.

Authors:  R M Ings; J P Fillastre; M Godin; A Leroy; G Humbert
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

9.  Effects of AC-1370, a new semisynthetic cephalosporin, on phagocyte functions.

Authors:  H Ohnishi; H Kosuzume; H Inaba; M Okura; H Mochizuki; Y Suzuki; R Fujii
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

10.  Pharmacokinetics of cefpimizole in normal humans after single- and multiple-dose intravenous infusions.

Authors:  D B Lakings; J M Friis; R J Brown; H R Allen
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

View more
  1 in total

1.  Tolerance and disposition of cefpimizole in normal human volunteers after intramuscular administration.

Authors:  E Novak; D B Lakings; L M Paxton
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.